Increased PI3K and Akt activity has been observed in asthma models, and PI3K inhibitors have been demonstrated to suppress specific pathological symptoms, such as reduced chemokine expression in eosinophils, lower IL-5 and IL-13 levels in bronchoalveolar lavage fluid, reduced eosinophil infiltration in lung tissue, and decreased airway hyperresponsiveness [52,53]. The gene discussed is IL13; the disease is airway hyperresponsiveness.